A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for the Immunological and Histological Evaluation of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, rBet v1-FV

Trial Profile

A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for the Immunological and Histological Evaluation of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, rBet v1-FV

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2013

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Hypersensitivity
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Allergopharma
  • Most Recent Events

    • 26 Apr 2011 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 20 Apr 2011 Planned End Date identified as 1 Jun 2013, according to ClinicalTrials.gov.
    • 20 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top